Humacyte shares are continuing higher after the company on Monday announced it was granted Regenerative Medicine Advanced Therapy designation by the FDA for patients with advanced peripheral artery disease.
Portfolio Pulse from Benzinga Newsdesk
Humacyte shares are rising after the company received Regenerative Medicine Advanced Therapy designation from the FDA for treating advanced peripheral artery disease.
July 02, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Humacyte shares are experiencing an upward trend following the FDA's Regenerative Medicine Advanced Therapy designation for its treatment of advanced peripheral artery disease.
The FDA's Regenerative Medicine Advanced Therapy designation is a significant milestone for Humacyte, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100